142992-72-1

Basic information

• Product Name: Guanidine, (4-nitrophenyl)-, mononitrate
• Synonyms: Guanidine, (4-nitrophenyl)-, mononitrate;4-Nitrophenylguanidine nitrate;Guanidine, (4-nitrophenyl)-, Mononitrate (9CI);N-(4-Nitrophenyl)guanidine nitrate;1-(4-nitrophenyl)guanidine nitrate;2-(4-Nitro-phenyl)guanidine
• CAS NO: 142992-72-1
• Molecular Formula: C₇H₈N₄O₂*HNO₃
• Molecular Weight: 243
• Mol File: 142992-72-1.mol
• Article Data: 7

Chemical Properties

• Appearance: /
• Storage Temp.: Sealed in dry,Room Temperature
• CAS DataBase Reference: Guanidine, (4-nitrophenyl)-, mononitrate(CAS DataBase Reference)
• NIST Chemistry Reference: Guanidine, (4-nitrophenyl)-, mononitrate(142992-72-1)
• EPA Substance Registry System: Guanidine, (4-nitrophenyl)-, mononitrate(142992-72-1)

Safety Data

• Hazardous Substances Data: 142992-72-1(Hazardous Substances Data)

Usage

General Description

Guanidine, (4-nitrophenyl)-, mononitrate is a chemical compound with the molecular formula C7H8N4O4. It is a nitrate derivative of guanidine and consists of a guanidine group linked to a 4-nitrophenyl group. Guanidine, (4-nitrophenyl)-, mononitrate is commonly used in organic synthesis as a reagent for the preparation of various organic compounds. It is also used as a precursor in the production of pharmaceuticals and agrochemicals. Guanidine, (4-nitrophenyl)-, mononitrate is known for its high reactivity and is used in a wide range of chemical reactions, including nucleophilic substitution and condensation reactions. However, it is important to handle this compound with care due to its potentially hazardous nature.

Upstream product

• 420-04-2 CYANAMID 
• 100-01-6 4-nitro-aniline 
• 15873-51-5 4-nitroaniline hydrochloride 

Downstream Products

• 181065-58-7 N-(4-nitrophenyl)-4-(pyridin-3-yl)pyrimidin-2-amine 
• 1215292-27-5 2-(4-nitroanilino)-5,7-dihydro-6H-pyrimido[5,4-d][1]benzazepin-6-one 
• 677752-97-5 4-{4-[2-(4-nitro-phenylamino)-pyrimidin-4-yl]-benzenesulfonyl}-piperazine-1-carboxylic acid tert-butyl ester 
• 136437-14-4 C₁₁H₁₂N₄O₆ 
• 136436-76-5 C₁₃H₁₆N₄O₆ 
• 136437-16-6 C₂₃H₂₀N₄O₆ 

Relevant articles and documents

7-(2-anilinopyrimidin-4-yl)-1-benzazepin-2-ones designed by a “cut and glue” strategy are dual aurora a/vegf-r kinase inhibitors

Although overexpression and hyperactivity of protein kinases are causative for a wide range of human cancers, protein kinase inhibitors currently approved as cancer drugs address only a limited number of these enzymes. To identify new chemotypes addressing alternative protein kinases, the basic structure of a known PLK1/VEGF-R2 inhibitor class was formally dissected and reassembled. The resulting 7-(2-anilinopyrimidin-4-yl)-1-benzazepin-2-ones were synthesized and proved to be dual inhibitors of Aurora A kinase and VEGF receptor kinases. Crystal structures of two representatives of the new chemotype in complex with Aurora A showed the ligand orientation in the ATP binding pocket and provided the basis for rational structural modifications. Congeners with attached sulfamide substituents retained Aurora A inhibitory activity. In vitro screening of two members of the new kinase inhibitor family against the cancer cell line panel of the National Cancer Institute (NCI) showed antiproliferative activity in the single-digit micromolar concentration range in the majority of the cell lines.

2-Anilino-4-(thiazol-5-yl)pyrimidine CDK Inhibitors: Synthesis, SAR Analysis, X-ray Crystallography, and Biological Activity

Following the identification through virtual screening of 4-(2,4-dimethyl-thiazol-5-yl)pyrimidin-2-ylamines as moderately potent inhibitors of cyclin-dependent kinase-2 (CDK2), a CDK inhibitor analogue program was initiated. The first aims were to optimize potency and to evaluate the cellular mode of action of lead candidate molecules. Here the synthetic chemistry, the structure-guided design approach, and the structure-activity relationships (SARs) that led to the discovery of 2-anilino-4-(thiazol-5-yl)pyrimidine ATP-antagonistic CDK2 inhibitors, many with very low nM Kis against CDK2, are reported. Furthermore, X-ray crystal structures of four representative analogues from our chemical series in complex with CDK2 are presented, and these structures are used to rationalize the observed biochemical SARs. Finally results are reported that show, using the most potent CDK2 inhibitor compound from the current series, that the observed antiproliferative and proapoptotic effects are consistent with cellular CDK2 and CDK9 inhibition.

N-PHENYL-2-PYRIMIDINE-AMINE DERIVATIVES AND PROCESS FOR THE PREPARATION THEREOF

The present invention relates to an N-phenyl-2-pyrimidine-amine derivative showing a superior effect on tumor, lung cancer, gastric cancer, etc. of warm-blooded animals and its salt. The present invention also relates to a process for preparing the compound and a pharmaceutical composition for the prevention and treatment of such diseases as tumor, lung cancer, gastric cancer, etc., which comprises the compound as an active ingredient.